Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Receivables - Other (2016 - 2023)

Historic Receivables - Other for Fortress Biotech (FBIO) over the last 10 years, with Q4 2023 value amounting to $100000.0.

  • Fortress Biotech's Receivables - Other fell 9473.68% to $100000.0 in Q4 2023 from the same period last year, while for Dec 2023 it was $100000.0, marking a year-over-year decrease of 9473.68%. This contributed to the annual value of $100000.0 for FY2023, which is 9473.68% down from last year.
  • Per Fortress Biotech's latest filing, its Receivables - Other stood at $100000.0 for Q4 2023, which was down 9473.68% from $300000.0 recorded in Q1 2023.
  • Over the past 5 years, Fortress Biotech's Receivables - Other peaked at $1.9 million during Q4 2022, and registered a low of $100000.0 during Q2 2022.
  • Its 5-year average for Receivables - Other is $647058.8, with a median of $400000.0 in 2019.
  • In the last 5 years, Fortress Biotech's Receivables - Other surged by 14691.36% in 2019 and then crashed by 9473.68% in 2023.
  • Quarter analysis of 5 years shows Fortress Biotech's Receivables - Other stood at $1.4 million in 2019, then grew by 14.29% to $1.6 million in 2020, then changed by 0.0% to $1.6 million in 2021, then grew by 18.75% to $1.9 million in 2022, then tumbled by 94.74% to $100000.0 in 2023.
  • Its Receivables - Other was $100000.0 in Q4 2023, compared to $300000.0 in Q1 2023 and $1.9 million in Q4 2022.